Mulpleta Side Effects Center

Last updated on RxList: 3/30/2022
Mulpleta Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Mulpleta?

Mulpleta (lusutrombopag tablets) is a thrombopoietin receptor agonist indicated for the treatment of low platelet counts (thrombocytopenia) in adult patients with chronic liver disease who are scheduled to undergo a procedure.

What Are Side Effects of Mulpleta?

Common side effects of Mulpleta include:

  • headache

Dosage for Mulpleta

The recommended dosage of Mulpleta is 3 mg orally once daily with or without food for 7 days. Begin Mulpleta dosing 8-14 days prior to a scheduled procedure. Patients should undergo their procedure 2-8 days after the last dose.

What Drugs, Substances, or Supplements Interact with Mulpleta?

Mulpleta may interact with other drugs. Tell your doctor all medications and supplements you use.

Mulpleta During Pregnancy or Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Mulpleta; it is unknown how it would affect a fetus. It is unknown if Mulpleta passes into breast milk. Because of the potential for adverse effects on nursing infants, breastfeeding is not recommended while using Mulpleta.

Additional Information

Our Mulpleta (lusutrombopag tablets) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Hepatitis C, Hep B, Hep A: Symptoms, Causes, Treatment See Slideshow
Mulpleta Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

You could develop a blood clot if your platelet count gets too high while you are taking lusutrombopag. Call your doctor or get emergency medical help if you have:

  • sudden numbness or weakness (especially on one side of the body);
  • problems with vision or speech;
  • swelling or redness in an arm or leg;
  • fever, chills;
  • stomach pain (upper right side), vomiting;
  • jaundice (yellowing of the skin or eyes); or
  • bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.

Common side effects may include:

  • headache.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Mulpleta (Lusutrombopag Tablets)

QUESTION

Long-term heavy alcohol consumption can cause: See Answer
Mulpleta Professional Information

SIDE EFFECTS

The following serious adverse reactions are discussed in detail in other sections of the labeling:

  • Thrombotic/Thromboembolic Complications [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of MULPLETA was evaluated in 3 randomized, double-blind, placebo-controlled trials, L-PLUS 1, L-PLUS 2, and M0626, in which patients with chronic liver disease and thrombocytopenia were treated with MULPLETA (N=171) or placebo (N=170) at a dose of 3 mg daily for up to 7 days prior to a scheduled procedure.

The majority of patients were males (59%), and median age was 61 years (range 19-88). The racial and ethnic distribution was White (50%), Asian (47%), Black (<1%), and Other (3%).

The most common adverse reactions (those occurring in at least 3%) in the MULPLETA-treated group across the pooled data from the three trials are summarized in table 1.

Table 1: Adverse Reactions with a Frequency ≥3% in Patients Treated with MULPLETA (Pooled Data (L-PLUS 1, L-PLUS 2, and M0626))

Adverse Reaction* MULPLETA 3 mg
(N=171) %
Placebo
(N=170) %
Headache 5 4

The incidence of serious adverse events was 5% (9 of 171 patients) in the MULPLETA group and 7% (12 of 170 patients) in the placebo group. The most common serious adverse reaction reported with MULPLETA was portal vein thrombosis [see WARNINGS AND PRECAUTIONS]. No adverse reactions resulted in discontinuation of MULPLETA.

Read the entire FDA prescribing information for Mulpleta (Lusutrombopag Tablets)

© Mulpleta Patient Information is supplied by Cerner Multum, Inc. and Mulpleta Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors